Veronika Lukacs‐Kornek

University of Bonn — Germany

Immunology and Microbiology · Life Sciences

24h-index5.6kcitations62works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(20), T-cell and B-cell Immunology(16), Immune Cell Function and Interaction(10), Immune Response and Inflammation(6), Liver Disease Diagnosis and Treatment(5)

Publications62 total

Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025· 1 citedOpen Access
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Data from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S7 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Global matrisome changes in obese lung are linked to fibroblastic stroma and premature aging
Cell Reports·2025Open Access
What we missed then, AI sees now: Revisiting legacy large extracellular vesicle data to reveal synergistic biomarkers for liver cancer screening
JHEP Reports·2025· 1 citedOpen Access
T cells in cancer: mechanistic insights and therapeutic advances
Biomarker Research·2025· 8 citedOpen Access
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Molecular Cancer Therapeutics·2025· 4 cited
Liquid biopsy in organ damage: introduction of an innovative tool for assessing the complexity of blunt splenic injury
European journal of medical research·2025· 1 citedOpen Access
Isolation, Purification, and Comprehensive Flow Cytometry Assessment of Lung Stromal Cells
Current Protocols·2024· 3 citedOpen Access
Liquid Biopsy als innovatives Tool für die Detektion der Schwere einer traumatischen Milzverletzung
Zeitschrift für Gastroenterologie·2024
Liquid Biopsy bei Thoraxtrauma- Erhebung erster Ergebnisse
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie·2024
page 1 of 4Next →

Frequent Co-authors

Shannon J. Turley(17), Deepali Malhotra(10), Maria A. González-Carmona(10), Anne Fletcher(9), Kutlu G. Elpek(8), Christian Kurts(8), Hanno Matthaei(7), Jörg C. Kalff(7), Santiago González(6), Michael C. Carroll(6), Racha Hosni(6), Niklas Klümper(6), Christine Sanders(6), Sana Hosni(6), Vittorio Branchi(6), Alexander Semaan(6), Abdullah Alajati(6), Natalie Pelusi(6), Susanna S. Ng(6), Damian J. Ralser(6)